Lisaftoclax vs Surzetoclax
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCL-2 · full Multiple Myeloma pipeline
Lisaftoclax
Marketed by Ascentage Pharma Group Inc.
NCT04674514 · Phase 1/2 · status unknown
This is a non-randomized, open-label dose-escalation study with no control group, primarily designed to establish a tolerable dose rather than to prove efficacy. Results have not yet been posted.
No aligned efficacy figure on record for this race.
Surzetoclax
Developed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2030 · NCT06953960 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lisaftoclax | Surzetoclax |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| VGPR or better | —Not reported | —Not reported |
| MRD negativity | —Not reported | —Not reported |
PFS, median
- Lisaftoclax
- —Not reported
- Surzetoclax
- —Not reported
OS, median
- Lisaftoclax
- —Not reported
- Surzetoclax
- —Not reported
ORR
- Lisaftoclax
- —Not reported
- Surzetoclax
- —Not reported
VGPR or better
- Lisaftoclax
- —Not reported
- Surzetoclax
- —Not reported
MRD negativity
- Lisaftoclax
- —Not reported
- Surzetoclax
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Lisaftoclax: no structured comparison results are available for Multiple Myeloma.
Surzetoclax: no structured comparison results are available for Multiple Myeloma.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lisaftoclax's landscape · Surzetoclax's landscape